Alumis Inc. · NASDAQ:ALMS
Alumis — Jefferies Global Healthcare Conference 2025
27 slides from Alumis's conference presentation, June 2025
Slide 1: Jefferies Global Healthcare Conference Presentation
Jefferies Global Healthcare Conference Presentation June 2025 Transform Therapies. Reimagine Lives.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the “safe harb or” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of
Slide 3: Well Capitalized Company with Multiple Upcoming Expected Development Milestones and Extended Runway into 2027
Well Capitalized Company with Multiple Upcoming Expected Development Milestones and Extended Runway into 2027 〉Alumis – ACELYRIN merger created a late-stage clinical biopharma company dedicated to innovating, developing and commercializing transformative therapies for immune-mediated diseases 〉Diffe
Slide 4: Late-Stage Pipeline with Multiple Near-Term Catalysts
Late-Stage Pipeline with Multiple Near-Term Catalysts DEVEL OPMENT ANTICIPATED TAR GET PRE CL INICAL PHASE 1 PHASE 2 PHASE 3 MILEST ONES Moderate-to-Severe Early 1Q 2026: Phase 3 Plaque Psoriasis (PsO) topline data ESK-001 Systemic Lupus 2026: Phase 2b topline data Erythematosus (SLE) (TYK2) Add’l i
Slide 5: ESK-001: TYK2i Achieving Maximal Target Inhibition
ESK-001: TYK2i Achieving Maximal Target Inhibition
Slide 6: Extensive Genetic Insights Inform TYK2 Indications
Extensive Genetic Insights Inform TYK2 Indications TYK2 P1104A variant protective across indications of interest 〉 TYK2 P1104A Loss-of-kinase-function variant stands out in the human genome, conferring powerful protection from broad array of immune-mediated diseases 〉 Out-sized protection conferred
Slide 7: ESK-001 and A-005: A Highly Differentiated TYK2i Portfolio
ESK-001 and A-005: A Highly Differentiated TYK2i Portfolio ESK-001 〉 Maximal Target Inhibition Phase 3 dose fully inhibits TYK2 by every measure in skin and blood* 〉 High Response Oral Long term PASI and sPGA response rates competitive with high efficacy biologics 〉 Long Term Safety No major safety
Slide 8: Maximal Target Inhibition Led to 15-20% Increase in Clinical Response (PASI)
Maximal Target Inhibition Led to 15-20% Increase in Clinical Response (PASI) Maximal Target Inhibition Maintained Across 24-hour Clinical Outcomes at 28 Weeks Dosing Period (Phase 1 multidose trough PK) (OLE Phase 2, PASI as observed) 1000 ESK-001 Mean Trough Concentration (ng/mL) 100 93 Patients wi
Slide 9: OLE BID: Consistent Results Supporting Robustness of Methodology
OLE BID: Consistent Results Supporting Robustness of Methodology OLE Treatment: ESK-001 40 mg BID 100 STRIDE Washout Open Label Extension 93.0 20 mg BID 40 mg BID 89.2 90.3 90.3 89.4 40 mg QD 40 mg BID 81.5 82.7 Placebo 81.7 80.5 77.5 80 71.8 69.4 72.7 Patient with Response (%) 58.1 56.9 60 53.7 63.
Slide 10: PASI-75 Over Time for OLE mg BID Cohort by STRIDE Study Dose
PASI-75 Over Time for OLE 40 mg BID Cohort by STRIDE Study Dose Includes Patients from STRIDE Placebo, 20 mg BID, 40 mg QD and 40 mg BID Cohorts (mNRI) OLE Treatment: ESK-001 40 mg BID STRIDE Washout Open Label Extension 100 20 mg BID 40 mg BID 94.1 93.8 94.1 40 mg QD 88.2 87.5 40 mg BID 85.2 Placeb
Slide 11: Safety Profile of ESK-001 at Week 52: No Significant Safety Findings Throughout 52 Weeks
Safety Profile of ESK-001 at Week 52: No Significant Safety Findings Throughout 52 Weeks ESK-001 40 mg QD ESK-001 40 mg BID* Overall (N=82) (N=147) (N=164) n (%) EAIR n (%) EAIR n (%) EAIR Subjects with ≥ 1 TEAE 50 (61) 122.76 73 (50) 102.33 108 (66) 108.18 Subjects with ≥ 1 TE SAE1 2 (2) 3.10 4 (3)
Slide 12: Patient-reported Outcomes Throughout Week for Original mg BID
Patient-reported Outcomes Throughout Week 52 for Original 40 mg BID Robust and rapid improvements in quality of life and control of itch maintained over time 100 DLQI 0/1 100 Average pruritus NRS score <4 81.3 80 80 73.2 Proportion of Patients (%) Proportion of Patients (%) 58.5 61.3 60 60 40 40 20
Slide 13: Psoriasis: Current Treatment Landscape
Psoriasis: Current Treatment Landscape Maximal response is Achieved at Week 24 and Beyond PASI 75 Outcomes for Recent Psoriasis Studies (79 studies, 13 molecules) ESK-001 in OLE Percent of Patients Achieving PASI-75 Skyrizi IL-23 As Observed PASI 75 Cosentyx IL-17 Stelara IL-12/23 mNRI/NRI PASI 75 J
Slide 14: Psoriasis: Large Market with Significant Unmet Need for High Efficacy Oral
Psoriasis: Large Market with Significant Unmet Need for High Efficacy Oral PLAQUE PSORIASIS 〉 ~8M adults have plaque psoriasis in the United States, 1.5M with ~16M moderate-to-severe disease1 MODERATE-TO-SEVERE 〉 Treatment dominated by injectable biologics and sub-effective orals PATIENTS WORLDWIDE1
Slide 15: Psoriasis: 92% of Diagnosed Psoriasis Patients are Not Treated with a Biologic Therapy
Psoriasis: 92% of Diagnosed Psoriasis Patients are Not Treated with a Biologic Therapy* Untreated, Light Therapy Additional opportunity for patients with 29% preference for oral therapy with easy to use oral Many patients are sub-optimally treated with Topicals2 topicals, HCP desire to treat “early
Slide 16: Psoriasis: ESK-001 Phase 3 ONWARD Program
Psoriasis: ESK-001 Phase 3 ONWARD Program Three Studies: Two parallel Phase 3 studies and a long-term extension (LTE) study Treatment Period Maintenance ONWARD3 (Long-term extension) ESK-001, 40mg BID (N=420) 2:1:1 Randomization Wk 16: ESK-001 (Open Label) Rollover to N= 840 Placebo (N=210) ESK-001
Slide 17: SLE: Ongoing Phase 2b Program (LUMUS) is Designed for Speed to Market and Probability of Clinical Success
SLE: Ongoing Phase 2b Program (LUMUS) is Designed for Speed to Market and Probability of Clinical Success 〉 High unmet need for safe and effective treatment in SLE – No oral targeted treatments available at this time – Opportunity to expand into lupus nephritis, cutaneous lupus 〉 Multiple points of
Slide 18: LUMUS Trial Incorporates Key Learnings from Past SLE Trials
LUMUS Trial Incorporates Key Learnings from Past SLE Trials Lupus Clinical Development Challenges Alumis Success Factors to Mitigate Challenges 〉 High placebo response rates responsible for 〉 LUMUS trial requires stringent disease failed SLE trials driven by: activity criteria – Insufficient disease
Slide 19: Kaken Collaboration and Licensing Agreement Secures Key Market for ESK-001 Global Commercialization Strategy
Kaken Collaboration and Licensing Agreement Secures Key Market for ESK-001 Global Commercialization Strategy Deal Background and Terms Alumis-Kaken Collaboration for ESK-001 in 〉 Kaken: Specialty pharmaceutical company in Japan with strong Dermatology in Japan experience in developing and commercial
Slide 20: Lonigutamab: Next Generation Anti-IGF-1R
Lonigutamab: Next Generation Anti-IGF-1R
Slide 21: Lonigutamab
Lonigutamab A Next-Generation Subcutaneous Anti-IGF-1R Therapy With Best-in-Class Potential in TED Lonigutamab Development Plan 〉 Capital Investment: Initial commitment of approximately $25- $50M to evaluate potential differentiation in TED; investment has been included in plan for cash runway into
Slide 22: A-005: First-in-Class, CNS-Penetrant Allosteric TYK2 Inhibitor
A-005: First-in-Class, CNS-Penetrant Allosteric TYK2 Inhibitor
Slide 23: A-005 Achieved Significant Dose-Dependent Response Preclinically
A-005 Achieved Significant Dose-Dependent Response Preclinically In Both Prophylactic and Therapeutic EAE Models (MOG peptide) with Once-Daily Oral Dosing Prophylactic EAE Therapeutic EAE 4 4 Mean clinical score + SEM Mean clinical score + SEM 3 Vehicle (n=10) 3 1 mg/kg A-005 (n=10) 2 3 mg/kg A-005
Slide 24: A-005 Demonstrated Ability to Cross Blood-Brain Barrier with High Levels of Exposure in CSF
A-005 Demonstrated Ability to Cross Blood-Brain Barrier with High Levels of Exposure in Cerebral Spinal Fluid (CSF) in Phase 1 CSF Cohort (120 mg QD) PK Summary: CSF Cohort (120 mg QD) Tmax Cmax C9h (h) (ng/mL) (ng/mL) Plasma Total , mean (SD) 1.5 (NA) 327 (0.6) 75 (16) Plasma Free , mean (SD) 1.5 (
Slide 25: Clinical Development Strategy for A-005
Clinical Development Strategy for A-005 Goal: Establish Clinical Proof-of-Concept in First Neuroinflammatory Indication by 2026 Positive Phase 1 Clinical Trial Completed 〉 Established CSF exposure and ability to maximally inhibit TYK2 across broad range of Ph2 doses 〉 Favorable safety profile at all
Slide 26: Recent Achievements and Anticipated Multiple Near-Term Milestones
Recent Achievements and Anticipated Multiple Near-Term Milestones 2025 2026 ✓ 1Q25 ESK-001 – PsO 52-Wk 1Q26 ESK-001 – PsO Phase 3 Topline Data Phase 2 OLE Data for Late-Breaker Presentation at AAD 2026 ESK-001 – SLE Phase 2b Topline Data ✓ 2Q25 Alumis / ACELYRIN Merger Close 2026 A-005 – MS Phase 2
Slide 27: Thank You!
Thank You! % alumis 27